Skip navigation
Please use this identifier to cite or link to this item:
Files in This Item:
File SizeFormat 
ARTIGO_TreatmentAmericanTegumentary.pdf397,03 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSilva, Juliana Saboia Fontenele ept_BR
dc.contributor.authorGalvão, Taís Freirept_BR
dc.contributor.authorPereira, Maurício Gomespt_BR
dc.contributor.authorSilva, Marcus Tolentinopt_BR
dc.identifier.citationSILVA, Juliana Saboia Fontenele e et al. Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence. Revista da Sociedade Brasileira de Medicina Tropical, Uberaba, v. 46, n. 6, p. 669-677, nov./dez. 2013. DOI: Disponível em: Acesso em: 14 set. 2020.pt_BR
dc.publisherSociedade Brasileira de Medicina Tropical - SBMTpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleTreatment of American tegumentary leishmaniasis in special populations : a summary of evidencept_BR
dc.subject.keywordLeishmaniose tegumentar americanapt_BR
dc.subject.keywordPopulações especiaispt_BR
dc.subject.keywordLeishmaniose - tratamentopt_BR
dc.rights.licenseRevista da Sociedade Brasileira de Medicina Tropical - (CC BY-NC) - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Fonte: Acesso em: 14 set. 2020.-
dc.description.abstract1We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fill in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.-
Appears in Collections:FMD - Artigos publicados em periódicos e preprints

Show simple item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/28692/statistics">

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.